Laura Deming
Co-Founder & CEO, Until. On 2 shows, 2 appearances. The Shows tab opens the full record on each.
investorfounderexecutivescientist@LauraDeming ↗LinkedIn ↗untillabs.com ↗Wikipedia ↗
After studying at MIT and receiving an inaugural Thiel Fellowship, Deming launched The Longevity Fund to back anti-aging biotechnology companies. She currently serves as co-founder and CEO of Until, developing reversible cryopreservation technology.
2shows
2appearances
22statements
6resolved
6supported
0contradicted
100%fully supported
4said about them ↓ Everything Laura Deming said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Deming: Longevity is counterintuitively the least risky sector in biology
“I literally thought it was the least risky, most likely to work part of biology in general, particularly the part of biology that would be easy to test in humans, and that's very counterintuitive to most people.”
Until aims for reversible whole-body cryopreservation after mastering single organ transplants
“Our long-term goal is reversible whole body cryopreservation for, you know, medical sort of hibernation. But in the near term, what we work on is reversibly cryopreserving human, single human organs to help transplant patients get organs more efficiently.”
Deming: Biotech VC is constrained by founder talent, not funding
“And so I think the fascinating thing is, you know, I always assumed from the outside that biotech venture capital was really limited by dollars, and I think it used to be, but I think the fascinating fact is now it's all about talent, and just, you know, we're…”
Deming: Biotech value stems from founder-driven decisions, not initial thesis
“And I think, you know, maybe sometimes focusing on the thesis of an investment can blind you to the fact that most of the value in biotech comes from the eventual trajectory of the company that's unpredictable at the start. And that trajectory is absolutely di…”
Deming: Society's failure to recognize aging as a disease hinders research
“I think longevity and aging kind of occupy this weird realm where because they're not like explicitly diseases in a way that's fully socially recognized yet, they're not seen as valid to work on.”
Deming: Brain injury tolerance remains the bottleneck for whole-body cryopreservation
“The big unknown to get to whole body reversible is the brain. It's unclear, like the brain can withstand a lot of change and does withstand a lot of different types of damage or change with age, for example. But it's unclear whether, like, what kind of injury …”
Deming: Rewarmed cryopreserved kidneys successfully restore normal organ function in rats
“Greg Faheed has done excellent work sort of looking at reversible cryopreservation in kidneys, and showing, like, you can reversibly cryopreserve a kidney, rewarm it, put it into a rat that does not have another kidney, and that rat returns to normal function …”
Deming: Biotech VC funding doubled while new startup creation remained flat
“I think one of the founding into biotech venture capital has doubled over the past couple years, and that's a huge fact, but the number of companies started to stay fairly stable”
Deming: All Longevity Fund portfolio companies target multi-disease pathways
“All the companies that we invest in have drugs that have worked not just in kind of mouse models of Alzheimer's typically, but also diabetes and heart disease, and kind of typically the pathways that we invest in have been tested in and work in almost every Ag…”
Deming: VC value creation is limited by rigid fund structure norms
“I think the diversity of fun types. I think we've been artificially constrained by a perception that it's hard to raise a new structure of fun because LPs just kind of, like, amorphously won't like it. I think that's really cut down on the value to be created …”
Deming: Medical hibernation carries severe psychological costs of losing social context
“And that will put a limit on, like, how much people want to use this for, like, I think there's, like, a real cost that, that kind of you incur. And so it's, in my mind, it only makes sense for, like, really serious use cases initially where, like, you literal…”
Deming: Cryobiology uniquely allows swapping biological complexity for engineering difficulty
“Not specific or something, but it is actually one of the core reasons why I think the problem is interesting to work on, which is that, like, you can trade off, like, engineering difficulty and biological difficulty to a non-zero degree. Like, not, not a hundr…”
Laura Deming: Three decades of research prove aging is genetically malleable
“There was really very little work on aging and longevity, but the past three decades have resulted in massive advances. So we now know that it's possible to genetically control aging, that aging is malleable.”
Deming: Internal biotech studio builds yield higher equity and easier LP pitches
“I mean, I think it's a great strategy. It's great for the VCs for certain parameters. I think the likelihood of success is slightly higher. The equity stakes are definitely higher, and there's a better pitch to LPs in the short term.”
Laura Deming: Raising a first VC fund is like a seed round
“But I think the process for raising your first fund is a lot more like raising a seed round for a company than it is like any kind of mature venture fundraising process I've seen.”
Laura Deming: The Longevity Fund pitched Unity Biotechnology to secure early LPs
“We had just found one of the first companies that we ever invested in, Unity Biotechnology, and we were really, really excited about them. And so I actually used that as the first Deal that I discussed with LPs.”
Deming: Immunotherapy raised metastatic melanoma ten-year survival to over 50 percent
“Like sort of in a single year, like metastatic melanoma went from being something that you had like a six to nine month prognosis, like less than a year of expected survival, to with like, you know, new combination immunotherapies, you might have a decade plus…”
Deming: Speeding through nucleation temperature ranges prevents tissue ice formation
“Ice sort of forms through a process of random nucleation and then extension. And this is cool because you can modulate the, like, sort of nucleation, the rate of nucleation and extension to then modulate the probability of ice formation. And because it's proba…”
Deming: Human embryos cryopreserved for over thirty years yield viable pregnancies
“There have been human embryos that were reversibly, that were, you know, cry preserved for the latest record was over 30 years, and then rewarmed and sort of viably used to create pregnancy, and then, you know, sort of like, there are kids who were literally c…”
Until simultaneously develops human organ cryopreservation and reversible whole-rat hibernation
“We work on the two in parallel. So we both work on scaling up preservation and rewarming technologies to kind of human organ scale. And also in parallel, we work on a sort of whole rat reversible hibernation and transitioning technologies over from sort of wha…”
Deming: Organ transplantation is severely bottlenecked by last-minute travel logistics
“Right now for matching, it's like everything's done at literally the last minute. It's like someone Dies and organ becomes available. And like, you're just kind of calling around trying to find, like, what patient is available to get this organ, and you don't …”
The other half of the tape: Laura Deming's own voice is left out of every number here. Other people bring the name up 4 times in 3 episodes across the shows. every mention, with the transcript →
Who brings them up most Fred Turner 2Sarah Guo 1Dylan Field 1
Every mention by year
tap a year for its mentions
20VC 3
No Priors 1
2026 3 mentions in 2 episodes 2 per episode
One line per show, most statements first. The link opens Laura's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
| NO PRIORSLEDGER | Co-Founder & CEO, Until | 1 | 12 | 100% 4/4 | full record on No Priors → |
| 20VCLEDGER | Co-Founder & CEO, Until | 1 | 10 | 100% 2/2 | full record on 20VC → |